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Thoracoscopic Assessment of Pleural Tumor Burden in
Patients with Malignant Pleural Effusion
Prognostic and Therapeutic Implications
Lama Sakr, MD,*† Fabien Maldonado, MD,†‡ Laurent Greillier, MD,† Herve´ Dutau, MD,†
Anderson Loundou, PhD,§ and Philippe Astoul, MD, PhD†
Background: Malignant pleural effusion (MPE) is encountered at
an advanced stage of disease progression and often heralds a poor
prognosis. The most reliable predictive factor of survival in such
patients is the primary tumor. Thoracoscopy is often performed for
accurate diagnosis and/or thoracoscopic talc insufflation as a thera-
peutic modality. It remains unknown whether pleural tumor burden,
as visualized on thoracoscopy, has potential prognostic value. The
objective of this study was to determine the prognostic accuracy of
pleural tumor extent and localization (parietal, visceral, or diaphrag-
matic involvement), as assessed during medical thoracoscopy.
Methods: Medical records of all patients who underwent thoracos-
copy for suspicion of MPE between 2001 and 2008 at a tertiary care
referral hospital were reviewed. Patients were included if pleural
metastatic invasion was confirmed on tissue biopsy and survival
status ascertained.
Results: Four hundred twenty-one patients underwent diagnostic or
therapeutic medical thoracoscopy at our referral center. Among
them, 122 had confirmed metastatic pleural spread, but survival data
were lacking in 15. Primary tumor consisted of non-mall cell lung
cancer in 56, breast cancer in 23, melanoma in eight, and other
malignancies in 20. Median survival of the entire population was 9.4
months. On univariate analysis, the following variables were signif-
icantly associated with reduced median overall survival: pleural
metastatic melanoma, age less than 60 years, bloody MPE, extensive
pleural adhesions, and widespread visceral pleural nodules (p 
0.05). On multivariate analysis, only melanoma as a primary tumor,
pleural fluid appearance and extent of pleural adhesions remained
independent and significant predictors of survival.
Conclusion: No significant association was found between the
extent or localization of pleural tumor burden and overall survival.
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Malignant pleural effusion (MPE) is frequently encoun-tered in patients with a variety of underlying malignan-
cies, at an advanced stage of disease progression. It heralds a
poor prognosis, with a median survival of 31–3 to 94 months
from the time of diagnosis, with the exception of breast and
ovarian carcinoma.5 Associated symptoms may consist of
significant dyspnea, poor exercise tolerance, and impaired
quality of life. Thoracoscopy allows a prompt and accurate
diagnosis, in addition to providing effective symptomatic
management with talc insufflation. The latter is a highly
effective procedure, achieving successful long-term pleu-
rodesis in more than 80% of cases.6–8 Before talc insufflation,
careful assessment of pleural carcinomatosis is usually
achieved. Interestingly, it remains unknown whether pleural
tumor burden—as assessed during thoracoscopy—has poten-
tial prognostic value.
It is generally believed that the most important predic-
tive factor of survival in patients with MPE is the primary
tumor.2,9 Karnofsky Performance Scale has been also proven
reliable in predicting prognosis, as a Karnofsky Performance
Scale score [metqu] 70 at presentation was associated with
better overall survival in patients with recurrent symptomatic
MPE.1 Other variables, such as pleural fluid (PF) pH and
glucose concentration, have been reported by some authors as
reliable prognostic factors, as low levels were indicative of
poor survival10–12; however, such association was not proven
in subsequent research,1,13,14 including a most recent prospec-
tively designed study.1
Some other potential prognostic factors deserve further
analysis. The extent of pleural carcinomatosis (EPC) ob-
served during thoracoscopy has been initially shown to cor-
relate closely but inversely with survival in patients with
MPE.11 Nevertheless, subsequent studies failed to prove such
a correlation.1,12 A locally developed scoring system was
used to grade the EPC in previous studies. Assessment of
costoparietal, visceral, and diaphragmatic pleura on thoraco-
scopic examination was done using a scale of 0 to 3 for each
pleural surface; the sum of individual scores, ranging from 0
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to 9, represented the final EPC score. Nevertheless, using
such a global score might not have allowed accurate assess-
ment of each individual pleural surface as a potential prog-
nostic marker. It has been previously suggested that initial
pleural metastases occur on the mediastinal and diaphrag-
matic pleura and that with disease progression, pleural inva-
sion spreads cephalad and costal.15 Therefore, it can be
hypothesized that extent and specific localization of meta-
static pleural involvement, as visualized on thoracoscopy,
could affect survival time. Recently, in a retrospective analysis
of 540 patients with MPE, pleural adhesion rating—assessed
thoracoscopically—correlated positively with pleural tumor
burden and inversely with median survival. Nevertheless, on
multivariate analysis, only tumor burden—but not the extent of
pleural adhesions—remained an independent prognostic fac-
tor.16 Moreover, although bloody pleural effusions (BPEs) have
been suggested to increase the probability of malignancy,9,17 no
data are available with regard to the prognostic importance of PF
appearance in MPE. In addition, it is not known whether cyto-
logical yield of PF—obtained by thoracentesis before eventual
thoracoscopy—has any potential prognostic value. If PF appear-
ance and PF cytological yield prove to be significant prognostic
factors, this might help avoid complex and invasive palliative
therapeutic procedures.
The primary objective of this study was to reevaluate
the prognostic accuracy of pleural tumor burden, by taking
into account the extent, pattern, and specific localization
(costoparietal, visceral, and diaphragmatic) of pleural malig-
nant invasion, as assessed during medical thoracoscopy. Sec-
ondary objectives were to determine or reassess other mor-
phologic and cytopathologic variables potentially indicative
of prognosis: primary tumor, PF appearance and cytological
yield, and the extent of pleural adhesions on thoracoscopic
examination.
MATERIALS AND METHODS
Medical records of all patients who underwent medical
thoracoscopy for suspicion of MPE between 2001 and 2008
at a French university hospital were reviewed. No ethical
considerations were raised. Patients were included if pleural
metastatic invasion was confirmed on pleural tissue biopsy
obtained at thoracoscopy. Patients with malignant pleural
mesothelioma (MPM) were excluded from the study. Eligible
subjects were also excluded if the date of death was missing
and the patient could not be confirmed alive by direct or
indirect source of information (through family members or a
recent doctor’s appointment).
Collected data included demographics (age and gen-
der), primary tumor origin, PF cytology on a most recent
sample obtained by thoracentesis before thoracoscopy, PF
appearance, thoracoscopic findings (grade of adhesions, ex-
tent, pattern, and localization of pleural metastatic spread
with separate evaluation of costoparietal, visceral, and dia-
phragmatic pleural surfaces), and date of death or the most
recent date at which the patient was confirmed alive.
Before thoracoscopy, patients were evaluated by an
interventional pulmonologist and an anesthesiologist, to as-
sess indication for diagnostic and/or therapeutic thoracoscopy
(thoracoscopic talc insufflation [TTI]) and to ensure safety of
the procedure, taking into account each patient’s overall
functional status and comorbid illnesses. Patients deemed fit
enough to undergo medical thoracoscopy were selected. Sub-
jects were either in- or outpatients known to our medical
center, or referrals from outside our university hospital.
Thoracoscopy was performed under general anesthesia, with
patients in a lateral decubitus position, lying on the nonaf-
fected side. Patients were intubated and maintained on spon-
taneous ventilation. Evacuation of PF was followed by care-
ful examination of the pleural cavity, and multiple biopsies,
using an optical biopsy forceps (Wolf, Knittelgen, Germany),
were then performed on tumoral and inflammatory areas over
the costoparietal pleura. TTI was subsequently achieved in all
patients. Finally, a 28-Fr chest tube was introduced and
directed toward the lung apex, where it was left in place for
48 hours.
A detailed description of thoracoscopic findings was
recorded by the operating physician in a dedicated report. PF
appearance was reported as bloody or nonbloody. Adhesions
within the pleural cavity were classified as (1) no adhesions,
(2) isolated adhesions allowing normal or near-normal tho-
racoscopic examination, and (3) more extensive adhesions
precluding complete and optimal visualization of the pleural
cavity. Visceral, costoparietal, and diaphragmatic pleura were
separately assessed for tumoral invasion and more specifically
for the pattern of tumoral spread (nodules, pleural thickening, or
pleural lymphangitis). Nodules were subsequently quantified as
isolated (reported as “unique nodule” or “few nodules”) or
multiple. Pleural lymphangitis was noted when reticular forma-
tions were visualized on the pleural surface during thoracoscopy.
Patient survival status or date of death was confirmed by careful
search of medical records, telephone calls to the patient or
his/her family, contact with patient’s treating physician, or by
consultation of civil records at city hall. Patient survival was
calculated from the time of thoracoscopy.
Statistical Analysis
The Kaplan-Meier method was used to determine the
relationship between patient survival and pleural tumor bur-
den (extent, pattern, and localization), in addition to other
potential prognostic factors (age, gender, primary tumor, PF
appearance and cytological yield, and the extent of adhe-
sions). The 95% confidence interval was calculated, and
log-rank test was used for comparison. To analyze the inde-
pendent prognostic contribution of each variable, a Cox
regression analysis was performed. Results were considered
statistically significant at p less than 0.05. All analyses were
performed with statistical software (SPSS for Windows, re-
lease 15.0, SPSS, Chicago, IL).
RESULTS
Between 2001 and 2008, 421 patients underwent diag-
nostic and/or therapeutic medical thoracoscopy at our referral
tertiary care hospital. Among those, 122 patients had meta-
static pleural spread, as confirmed by thoracoscopic pleural
biopsy. Fifteen were excluded, as their survival status or
exact date of death could not be ascertained. One hundred
seven patients (mean age, 61 years; 50 men and 57 women)
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were included in the final analysis. Primary tumor consisted
of non-small cell lung cancer in 56 patients, melanoma in
eight, breast carcinoma in 23, and other malignancies in 20
patients (Table 1). Pleural effusion was right sided in 57
patients (53%) and hemorrhagic in 61 (57%). Pleural adhe-
sions were absent in 64 patients (60%), limited in eight (7%),
and extensive in 35 (33%). Invasion of parietal pleura was
found in the great majority of patients (105/107, 98%),
whereas visceral pleural involvement was observed in 87/107
(81%). Diaphragmatic pleura were deemed malignant in 60
of 107 patients and normal in two. Data with respect to
diaphragmatic pleural involvement were missing in 45 pa-
tients. Mediastinal pleural involvement was rarely reported.
Most often, mediastinal pleura is not visualized on medical
thoracoscopy; therefore, we did not account for mediastinal
pleural invasion in our assessment of pleural carcinomatosis.
The pattern and extent of pleural metastatic spread are de-
scribed in detail in Table 2. PF cytology—assessed on tho-
racentesis before thoracoscopy—was positive in 78 patients
and negative in 19. PF cytology results were not available in
10 patients.
Median survival of the entire study population was 9.4
months (Figure 1). Median survival values derived from the
Kaplan-Meier analysis for each of the potential prognostic
factors are listed in Table 2. Pleural metastatic melanoma, age
less than 60 years, BPE, and extensive pleural adhesions were
all reliable predictive factors on univariate analysis, as they
were all associated with significantly reduced median overall
survival (p  0.05). When pleural tumor burden was further
categorized, visceral pleural nodules (“multiple” category)
were associated with significantly lower median survival. For
unexplained reasons, parietal pleural nodules (“few” category)
and diaphragmatic pleural lymphangitis were associated with
better prognosis on univariate analysis. Such correlation did not
remain significant on multivariate analysis of survival. No dif-
ference in overall survival was found between patients with
cytologically positive and negative pleural effusions.
Using the multivariate model of survival, only melanoma
as the primary tumor, PF appearance and extent of pleural
adhesions remained as independent and significant predictors of
survival (p  0.03, 0.02, and 0.03, respectively) (Table 3).
DISCUSSION
The primary objective of this study was to assess the
prognostic accuracy of pleural tumor burden in patients who
undergo thoracoscopy for MPE. Secondary objectives were
to determine the contribution of additional morphologic and
clinicopathologic parameters at predicting survival.
As stated earlier, patients with MPM were excluded
from the study. In fact, MPM is a rare and aggressive
malignancy, with a distinct profile and biological behavior.
The epidemiological background, natural history, staging
system, therapeutic modalities, and prognosis are widely
different from those of primary lung cancer or other primary
carcinomas metastatic to the pleura. Boutin et al. have pre-
viously shown that MPM—in contrast to metastatic pleural
spread—arises in the parietal and diaphragmatic pleura and
later spreads to the visceral pleura. In their prospective study,
patients with early disease involving only the ipsilateral
parietal pleura (T1a) had a median survival of 32 months,
whereas those with slightly more advanced tumor involving
all pleural surfaces, including the visceral pleural (T1b), had
a median survival of 7 months.18 Such findings contributed to
the elaboration of a new international staging system for
MPM.19 Therefore, given the distinct features of this malignant
entity, we chose to exclude patients with MPM from our study.
In contrast to previous studies, pleural tumor burden
prognostic accuracy was assessed by separately considering
the malignant involvement of each pleural surface. It is worth
noting that mediastinal pleura are not often visualized on
standard medical thoracoscopy, and therefore, related data
could not be obtained. Although our scoring system was not
previously validated, we believed that it might provide a
more precise description of the pattern and localization of
pleural malignant invasion. Nevertheless, no significant as-
sociation was found between the extent, pattern, or localiza-
tion of pleural carcinomatosis and overall survival. This is in
agreement with the findings of Burrows et al. and Sanchez-
Armengol and Rodriguez-Panadero,1,12 using a broader lo-
cally developed scoring system for assessment of the EPC.
On the other hand, although metastatic pleural mela-
noma accounted for only 8% of our cohort, it was associated
with significantly reduced median overall survival. The latter
might suggest that the extent or pattern of pleural metastatic
involvement in itself is not a prognostic factor; rather, a MPE
is perhaps simply indicative of advanced disease stage, and
survival could be mainly determined by the primary tumor
and its inherent characteristics, namely its degree of aggres-
sion and its response to chemotherapeutic treatments. Inter-
estingly, outcome was not statistically different between the
larger and clinically more important groups of metastatic
pleural lung and breast carcinomas, in contrast to previous
TABLE 1. Tumor Type in Patients with Malignant Pleural
Effusion
Tumor Types n (%)
Lung
Adenocarcinoma 47
Squamous 6
Squamous  adenocarcinoma 1
Small cell 3
Large cell neuroendocrine 1
Undifferentiated 1
Melanoma 8
Breast 23
Ovary 4
Kidney 4
Prostate 2
Gynecological 1
Pancreas 1
Gastrointestinal 1
Esophagus 1
Thyroid (medullary) 1
Undifferentiated 1
Adenocarcinoma (unknown origin) 1
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reports. A relatively small number of patients in each cate-
gory, and therefore, a poor statistical power could have
accounted for our findings.
Curiously, PF appearance was significantly correlated
with overall survival. A bloody MPE was independently
associated with poor prognosis. A previous study has shown
that a BPE slightly increases the risk of underlying malig-
nancy and that MPEs were bloody in 11% of cases.17 Nev-
ertheless, no data were previously available with respect to
the prognostic importance of a bloody malignant PE. The
latter usually develops after direct tumor invasion of blood
vessels, occlusion of venules, tumor-induced angiogenesis, or
TABLE 2. Variables Predicting Overall Survival in Patients with Malignant Pleural Effusion (Univariate Analysis)
Variables Value n (%)
Median
Survival (d)a 95% CI
Hazard
Ratiob 95% CI pc
Primary tumor NSCLC 56 297 196–398 1
Melanoma 8 42 0–115 2.3 1.08–4.89 0.03
Breast 23 424 387–461 0.66 0.38–1.14 0.14
Other 20 128 0–345 1.3 0.76–2.23 0.34
Sex Male 50 260 103–417 1
Female 57 317 177–457 0.81 0.54–1.23 0.32
Age (yr) 60 51 217 85–349 1
60 56 382 219–545 0.64 0.42–0.96 0.03
Effusion side Left 50 251 174–328 1
Right 57 338 202–474 1.11 0.73–1.67 0.63
PF cytology on thoracentesis Negative 19 220 0–472 1
Positive 78 252 167–337 0.82 0.48–1.40 0.46
PF appearance Nonbloody 46 471 258–684 1
Bloody 61 215 82–348 2.18 1.41–3.36 0.001
Grade of adhesions No adhesions 64 405 323–487 1
Limited adhesions 8 127 0–636 0.92 0.40–2.15 0.85
Large adhesions 35 118 61–175 2.4 1.52–3.77 0.001
Parietal pleural nodules No nodules 20 142 0–412 1
Nodules 87 317 208–426 0.74 0.44–1.23 0.24
Parietal pleural nodules No nodules 20 142 0–412 1
Few nodules 5 617 480–754 0.23 0.07–0.80 0.02
Multiple nodules 82 265 150–380 0.8 0.48–1.33 0.38
Parietal pleural pachypleuritis No pachypleuritis 67 342 208–476 1
Pachypleuritis 40 215 65–365 1.02 0.67–1.56 0.93
Parietal pleural lymphangitis No lymphangitis 69 260 191–329 1
Lymphangitis 38 342 38–646 0.77 0.50–1.18 0.24
Visceral pleural invasion No invasion 17 530 342–718 1
Invasion 87 260 180–340 1.81 0.98–3.34 0.06
Visceral pleural nodules No nodules 46 400 274–526 1
Nodules 58 217 106–328 1.43 0.94–2.20 0.1
Visceral pleural nodules No nodules 46 400 274–526 1
Few nodules 14 342 0–744 0.88 0.46–1.70 0.71
Multiple nodules 44 163 65–261 1.8 1.14–2.85 0.01
Visceral pleura pachypleuritis No pachypleuritis 69 317 147–487 1
Pachypleuritis 35 260 181–339 1.24 0.80–1.91 0.34
Visceral pleura lymphangitis No lymphangitis 82 338 244–432 1
Lymphangitis 22 158 50–266 1.33 0.81–2.20 0.26
Diaphragmatic pleural nodules No nodules 7 158 35–281 1
Nodules 55 361 227–495 0.78 0.35–1.73 0.54
Diaphragmatic pleural pachypleuritis No pachypleuritis 53 382 294–470 1
Pachypleuritis 9 185 7–363 0.72 0.32–1.63 0.44
Diaphragmatic pleural lymphangitis No lymphangitis 51 340 238–442 1
Lymphangitis 11 729 439–1019 0.46 0.23–0.92 0.03
a Kaplan-Meier survival estimates.
b Cox proportional hazards model.
c Log-rank (Mantel-Cox) p value.
CI, confidence interval; NSCLC, non-small cell lung cancer; PF, pleural fluid.
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 Thoracoscopic Assessment of Pleural Tumor Burden
Copyright © 2011 by the International Association for the Study of Lung Cancer 595
increased capillary permeability due to vasoactive cytokines
and chemokines.20,21 Vascular endothelial growth factor
(VEGF) is a potent growth factor for endothelial cells and is
believed to be a key mediator in the formation of MPE. In
fact, it has been shown that MPE contained significantly
higher levels of VEGF than effusions of inflammatory etiol-
ogy.22 Moreover, hemorrhagic effusions have shown signif-
icantly higher VEGF levels than nonhemorrhagic effusions.22
In a recent prospective study, a significant positive correla-
tion was found between the number of red blood cells and
VEGF values in MPE; in addition, high VEGF levels in PF
was a significant negative predictor of patient survival.23
Moreover, the extent of pleural adhesions correlated
with lower survival expectancy, in accordance with the find-
ings of Bielsa et al.16 Nevertheless, in contrast to the latter
study, such correlation remained statistically significant on
multivariate analysis. Pleural adhesions are thought to de-
velop in the pleural space in response to several inflammatory
stimuli, including infection, malignancy and trauma.24 Pleural
inflammation is associated with an influx of a large number of
cytokines and inflammatory cells, which initiate a cascade of
cellular processes ultimately leading to collagen synthesis,
tissue remodeling, and pleural fibrosis. Tumor necrosis fac-
tor- and transforming growth factor- are examples of
mediators strongly implicated in the pathogenesis of pleural
inflammation and fibrosis. As a result of cytokine-induced
pleural injury and increased microvascular permeability, a
coagulation cascade is initiated, and components of both the
fibrinolytic system and inhibitors of the fibrinolytic system
are produced.25,26 Plasminogen, as well as plasminogen acti-
vators and plasminogen activator inhibitors (PAI-1 and PAI-
2), are readily detectable in inflammatory PFs.26 Whether the
extent of underlying intrapleural inflammatory and procoagu-
lation responses could induce or reflect a systemic hyperco-
aguable state, which might lead to fatal thromboembolic
disease, thereby accounting for worse short-term survival,
deserves further study.
FIGURE 1. Kaplan-Meier curve
showing median overall survival of
the study population. Median sur-
vival of the entire group was 9.4
months.
TABLE 3. Variables Predicting Overall Survival in Patients
with Malignant Pleural Effusion (Multivariate Analysis)
Variables
Hazard
Ratio 95% CI p
Primary tumor 0.04
NSCLC 1 — —
Melanoma 2.84 1.20–6.75 0.02
Breast 0.73 0.38–1.41 0.36
Others 0.81 0.42–1.54 0.51
Age 0.76 0.47–1.25 0.28
Sex 1.03 0.60–1.76 0.93
PF appearance 1.89 1.10–3.28 0.02
Grade of adhesions 0.02
No adhesions 1 — —
Limited adhesions 0.86 0.33–2.28 0.76
Large adhesions 2.2 1.23–3.94 0.01
Parietal pleural nodules 0.07
No nodules 1 — —
Few nodules 0.22 0.06–0.84 0.03
Multiple nodules 0.93 0.46–1.86 0.83
Visceral pleural invasion 0.77 0.34–1.78 0.55
Visceral pleural nodules 0.65 0.35–1.23 0.18
Diaphragmatic pleural lymphangitis 0.51 0.23–1.15 0.10
NSCLC, non-small cell lung cancer; PF, pleural fluid; CI, confidence interval.
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In this study, there was no significant difference in
survival duration between patients with cytologically positive
and negative pleural effusions, as assessed on thoracentesis
before thoracoscopic examination. As described previously,
pleural malignant involvement in all our patients was ulti-
mately confirmed on pleural tissue biopsy. Therefore, PF
cytological yield is not a reliable prognostic marker; rather, a
negative cytology—in the absence of plausible alternative
diagnoses (i.e., infection)—warrants further investigation.
Our study has several potential limitations. Because of
the retrospective design of our study, some data (i.e., dia-
phragmatic pleural invasion) were not always available. Our
study population was also relatively small, preventing reli-
able assessment of potential prognostic markers in specific
tumor types. In addition, the scoring system used for grading
pleural tumor burden and the extent of adhesions requires
further validation. It is also worth noting that some findings,
such as PF appearance, are partly subjective, and a potential
bias could have, therefore, affected our results. Moreover,
tumor response to chemotherapy, although previously shown
to affect short-term survival in such patients, was not ac-
counted for in this study. Many patients were treated and
followed up outside our university hospital setting and were
most often referred to us solely for thoracoscopic manage-
ment of recurrent and symptomatic MPEs. Therefore, rigor-
ous follow-up data regarding response to systemic therapy
were not available. In addition, primary tumor types were
widely variable; therapeutic modalities and, more specifi-
cally, chemotherapeutic agents are therefore expected to be
significantly diverse, further complicating the assessment of
tumor response to treatment, and its contribution to overall
survival. As metastatic stage was ascertained in all patients,
we did not feel the need to collect further data with regard to
the extent of disease at the primary site or the presence of
metastatic disease beyond the pleural space. Whether such
information might have affected outcome could not be deter-
mined. Moreover, the success or failure of pleurodesis after
TTI could not be assessed after patient discharge from hos-
pital, as most patients were subsequently followed up outside
our tertiary care setting. Nevertheless, recent data show no
correlation between postpleurodesis lung expansion and clin-
ical outcome—including survival—in patients with recurrent
MPE.27 Finally, all patients who were included in this study
were medically fit to undergo diagnostic and therapeutic
thoracoscopy under general anesthesia; obviously, this does
not apply to all patients who present with a MPE.
In conclusion, the extent, pattern, and specific localiza-
tion of pleural carcinomatosis do not seem to portend a
significant prognostic value in patients with MPE. Neverthe-
less, other variables, namely melanoma as the primary tumor,
PF appearance, and the extent of pleural adhesions proved to
be important predictive survival factors.
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